McKesson (MCK) was upgraded to "Overweight" from "Neutral" at JPMorgan today.

Shares of the San Francisco-based company that's engaged in delivering pharmaceuticals, medical supplies and healthcare information technology were up about 2% in early morning trading.

JPMorgan analyst Lisa Gill also raised her price target on the shares to $189 from $167.

The analyst believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted.

Last week McKesson reported fourth-quarter fiscal 2017 adjusted earnings that exceeded analysts' expectations.

Stocks have rebounded following a sharp sell off last week. Jim Cramer believes the rebound is real and gives investors advice on how to play the market going forward.

More from Stocks

Nucor Shares Retreat Despite Nearly Doubling Q2 Earnings

Nucor Shares Retreat Despite Nearly Doubling Q2 Earnings

Microsoft Climbs After-Hours on Earnings Beat; Guidance to Be Announced on Call

Microsoft Climbs After-Hours on Earnings Beat; Guidance to Be Announced on Call

Dow Falls, Breaking 5-Day Winning Streak on Beige Book Trade-War Worries

Dow Falls, Breaking 5-Day Winning Streak on Beige Book Trade-War Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Nucor Retains Buy Recommendation From TheStreet Ratings

Nucor Retains Buy Recommendation From TheStreet Ratings